Viatris Inc. (VTRS) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Canonsburg, PA, United States. The current CEO is Scott Andrew Smith.
VTRS has IPO date of 1980-03-17, 32,000 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $16.02B.
Viatris Inc. is a global healthcare company headquartered in Canonsburg, Pennsylvania, that develops and distributes a diverse portfolio of prescription brand drugs, generic medications, complex generics, biosimilars, and active pharmaceutical ingredients across four geographic segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company operates across multiple therapeutic areas including noncommunicable and infectious diseases, oncology, immunology, endocrinology, and ophthalmology, offering medicines in various formats such as oral solids, injectables, and complex dosage forms. Viatris markets well-known pharmaceutical brands including Lyrica, Lipitor, EpiPen, Viagra, and Celebrex, along with biosimilar franchises such as Fulphila and SEMGLEE, distributing its products through a broad network of pharmaceutical wholesalers, retailers, specialty pharmacies, and e-commerce channels. Beyond medications, the company provides patient support services including diagnostic clinics, educational seminars, and digital health tools. The company maintains strategic partnerships with leading biotechnology firms to expand its innovative pipeline and global reach.
